CONMED vs Penumbra
Add, change or remove companies; up to four.
KIRA’s take AI analyst
I put CONMED and Penumbra side by side, using each one’s latest annual report. Here is what stands out:
- Penumbra is the larger business, with $1.4B of revenue in fiscal 2025 against $1.4B for CONMED.
- Penumbra grew revenue faster (17.5%, against 5.2%).
- Penumbra kept more of each dollar of sales as operating profit (13.5% operating margin, against 7.5%).
- Penumbra turned more of its sales into free cash flow (12.5% FCF margin, against 11.0%).
- Penumbra earned a higher return on the capital invested in it (18.8%, against 3.7%).
Who comes out ahead
Of the 11 measures where higher (or lower) is clearly better, how many each company leads.
CONMED
CNMD
1/11
Share count change
Penumbra
PEN
10/11
Revenue growth5-year growthGross marginOperating marginNet marginFCF marginReturn on capitalReturn on equityPiotroski F-scoreNet debt / EBITDA
Side by side
Best in the row
| Latest fiscal year | CNMD FY25 | PEN FY25 |
|---|---|---|
| Size | ||
| Market cap | $1.5B | $12.8B |
| Revenue | $1.4B | $1.4B |
| Free cash flow | $151M | $175M |
| Net income | $47.1M | $178M |
| Growth | ||
| Revenue growth | 5.2% | 17.5% |
| 5-year growth | 9.8% | 20.2% |
| Share count change | 0.0% | 0.1% |
| Profitability | ||
| Gross margin | 54.6% | 67.1% |
| Operating margin | 7.5% | 13.5% |
| Net margin | 3.4% | 12.7% |
| FCF margin | 11.0% | 12.5% |
| Return on capital | 3.7% | 18.8% |
| Return on equity | 4.7% | 13.8% |
| Balance sheet | ||
| Net debt | $794M | −$522M |
| Net debt / EBITDA | 5.1x | −2.5x |
| Dividends and buybacks | $24.7M | $0.0M |
| Valuation & quality | ||
| P/E | — | 79.7x |
| Piotroski F-score | 6 | 7 |
Ten years
Revenue
Operating margin
Free cash flow
Return on capital
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.